Answers are grounded in this paper and cite their sources.
Database analysis demonstrates improved outcome prediction with progesterone receptor status in breast cancer, suggesting routine inclusion when estimating endocrine therapy benefit.
When accurately measured, PgR status is an independent predictive factor for benefit from adjuvant endocrine therapy. Therefore, PgR status should be taken into account when discussing RR reductions expected from endocrine treatment with individual patients.
No takes yet. Share an insight, caveat, or question.
Bardou et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: